Loading...
Loading...
Gilead Sciences, Inc.
today announced detailed 24-week results
from a Phase 2 study (Study 102) evaluating a once-daily single tablet regimen
containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. A
regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200
mg was found to be similar to Stribild^® (elvitegravir 150 mg/cobicistat 150
mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the
percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks
of treatment. These findings were presented today in a latebreaker session
(Abstract #99LB) at the 20th Conference on Retroviruses and Opportunistic
Infections (CROI 2013) taking place in Atlanta.
“Given that HIV is now a chronic disease that can be managed with life-long
therapy, there remains a need for new treatment options that are well
tolerated,” said Andrew Zolopa, MD, Professor of Medicine, Infectious
Diseases, Stanford University School of Medicine and an investigator for Study
102. “In this study, a TAF-based single tablet regimen achieved comparable
viral suppression to Stribild while demonstrating improvement in renal and
bone safety indicators.”
In Study 102, HIV-positive treatment-naïve adult patients were randomized
(2:1) to receive the investigational TAF-based regimen or Stribild. At 24
weeks, 87 percent (n=97/112) of patients taking TAF and 90 percent (n=52/58)
of patients taking Stribild achieved HIV RNA (viral load) less than 50
copies/mL, based on the FDA snapshot algorithm (95 percent CI for the
difference: -15.7 percent to 5.9 percent for TAF vs. Stribild; p=0.36). There
were no statistically significant differences in the frequency and nature of
Grades 3-4 laboratory abnormalities, and the frequency and nature of adverse
events were similar between the two arms. Both regimens were generally well
tolerated.
“We are pleased with these positive Phase 2 data, which we believe demonstrate
that TAF-based single tablet regimens have the potential to play an important
role in HIV therapy,” said Norbert W. Bischofberger, PhD, Gilead's Executive
Vice President, Research and Development and Chief Scientific Officer. “Our
Phase 3 program for TAF is enrolling rapidly, and we look forward to sharing
initial results from the first pivotal study in 2014.”
In January 2013, Gilead announced the initiation of two Phase 3 trials,
Studies 104 and 111, which are examining
TAF/elvitegravir/cobicistat/emtricitabine compared to Stribild among HIV
patients new to therapy.
Topline results from Study 102 were announced in October 2012.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in